Endogena Therapeutics has developed a novel approach to regenerative medicine that’s not only scientifically compelling, but practical.
Endogena’s technology unlocks the body’s own stem cells for controlled tissue repair by small molecules. Its products use a dosing schedule that could move easily into the system already in place for intravitreal injections.
CEO Matthias Steger, PhD, MBA, sat down with retina specialist Firas Rahhal, MD, to discuss the Endogena approach in depth. They also discuss the compelling results seen so far in both animal models and in patients.
The company’s lead candidate is being developed to treat retinitis pigmentosa. The product has received Orphan Drug and Fast Track Designation from the FDA and is moving through Phase IIa clinical trials. Dr. Steger says the company expects to have data to share in early 2024. It’s also submitting an investigational new drug (IND) application for an age-related macular degeneration treatment later this month.
Listen to the podcast today to discover:
Resources
Endogena Therapeutics https://endogena.com
Firas Rahhal, MD https://ois.net/firas-m-rahhal-md